Funding for this research was provided by:
Academy of Finland (299200, 316664)
Wilhelm och Else Stockmanns Stiftelse
Novo Nordisk Fonden (OC0013659)
Juvenile Diabetes Research Foundation International (17-2013-7)
European Foundation for the Study of Diabetes
Received: 13 February 2020
Accepted: 9 May 2020
First Online: 19 May 2020
Ethics approval and consent to participate
: The study protocol was in accordance with the principles of the Declaration of Helsinki as revised in 2000 and was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Written informed consents were obtained from each FinnDiane patient.
: Not applicable.
: EBP has received lectures fee from Eli Lilly, Astra Zeneca, Sanofi, Boehringer Ingelheim and is an advisory board member of Sanofi. P–H.G. reports receiving lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi, SCIARC and being an advisory board member of AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. No other potential conflicts of interest relevant to this article were reported.